King of Prussia, PA – January 2024 – OCMS Bio, a leader in monoclonal antibody discovery and development, has announced its move into a new facility at 3700 Horizon Drive in King of Prussia, PA. The state-of-the-art space, managed by Protecs, will support the company’s growing preclinical pipeline and research initiatives.

The new facility provides OCMS Bio with expanded laboratory and office space, enhancing its ability to advance therapeutic antibody candidates for infectious diseases, oncology, and autoimmune disorders. This move marks a significant milestone for the company as it scales operations to meet increasing demand for its proprietary On-Cell mAb Screening (OCMS) technology and preclinical programs.

“We are excited to establish our new home at 3700 Horizon Drive,” said Paul Halpern, CEO. “This facility offers the infrastructure and resources needed to accelerate our antibody discovery efforts and drive our preclinical assets toward clinical development.”

Managed by Protecs, a leader in turnkey R&D facility solutions, the space is designed to support life sciences companies with cutting-edge lab capabilities. OCMS Bio’s expansion underscores its commitment to innovation and growth in the biotech sector.